Skip to main content

Solexa Hopes to Issue $100M Worth of New Equities or Debt

NEW YORK, May 19 (GenomeWeb News) - Solexa announced yesterday that it is trying to obtain permission from the US Securities and Exchange Commission to issue $100 million worth of securities, which may consist of common stock, preferred stock, warrants, debt, or any combination thereof.


The company has filed a universal shelf registration statement on Form S-3. If the statement is declared effective by the SEC, Solexa will be allowed to issue securities in one or more offerings up to a maximum aggregate offering amount of $100 million.


Earlier this year, Solexa raised around $60 million in a private stock placement.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.